Scancell Holdings plc (AIM:SCLP)
12.53
-0.01 (-0.04%)
Mar 5, 2026, 8:31 AM GMT
Scancell Holdings Revenue
Scancell Holdings had revenue of 4.71M GBP in the twelve months ending October 31, 2025. In the fiscal year ending April 30, 2025, Scancell Holdings had annual revenue of 4.71M.
Revenue
4.71M
Revenue Growth
n/a
P/S Ratio
27.59
Revenue / Employee
78.52K
Employees
60
Market Cap
129.98M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Apr 30, 2025 | 4.71M | - | - |
| Apr 30, 2024 | - | - | - |
| Apr 30, 2023 | 5.27M | - | - |
| Apr 30, 2022 | - | - | - |
| Apr 30, 2021 | - | - | - |
| Apr 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Apr 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| hVIVO | 54.47M |
| Bioventix | 13.12M |
| Arecor Therapeutics | 5.06M |
| PureTech Health | 4.66M |
| 4basebio | 1.78M |
| Ondine Biomedical | 1.18M |
| Avacta Group | 113.00K |
| ImmuPharma | -69.96K |
Scancell Holdings News
- 4 weeks ago - Scancell Holdings plc (SCNLF) Q2 2026 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - Scancell announces FDA clearance of IND application for global Phase 3 trial of iSCIB1+ in advanced melanoma - GlobeNewsWire
- 2 months ago - Scancell Holdings plc (SCNLF) Discusses SCOPE Phase II Data: iSCIB1+ Shows Improved Progression-Free Survival in Advanced Melanoma Transcript - Seeking Alpha
- 6 months ago - Scancell Holdings Plc (SCNLF) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 6 months ago - Scancell reports Business Update and Financial Results for the Year Ended 30 April 2025 - GlobeNewsWire
- 8 months ago - Scancell reports Phase 2 data showing strongly improved outcomes in Late-Stage Melanoma with its Immunobody® iSCIB1+ - GlobeNewsWire
- 1 year ago - PharmaJet and Scancell Sign Strategic Partnership Agreement for Development and Commercialization of a Needle-free DNA Vaccine for Advanced Melanoma - Business Wire
- 2 years ago - PharmaJet Partner, Scancell, Announces Positive Data from the First Stage of its Phase 2 Trial of Advanced Melanoma DNA Vaccine delivered Needle-free - Business Wire